Laboratory Corp of America Holdings (LH) Stock Price, Quote & News

Company Profile

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 336-584-5171

Fax: 336-436-1569

Website: www.labcorp.com

Address:

531 South Spring Street, Burlington, United States

PrivateProfiteersAnalyst Dec. 25 at 2:00 PM

Actionable Trade Alert for $LH: Market Context: $LH closed at $254.46, currently trading below both the 30-day MA (261.8) and 50-day MA (264.14), indicating bearish momentum. The RSI at 39.08 suggests that the stock is nearing oversold territory, which may lead to a potential reversal. Directional Bias: Given the RSI and the proximity to the 60-day low of 244.52, there is a possibility for a short-term bounce. However, the overall trend remains bearish until it breaks above the MAs. Suggested Trade Plan: - Entry: $254.46 - Stop Loss: $244.00 (below the 60D low for protection) - Take Profit Targets: 1. $261.00 (1st target, approx. 2.5% gain) 2. $270.00 (2nd target, approx. 6.1% gain) 3. $298.00 (3rd target, approx. 17.1% gain) This plan allows for a strategic approach with a favorable risk-reward ratio. Monitor price action closely for any changes. https://privateprofiteers.com

0 · Reply

ZacksResearch Dec. 22 at 1:57 PM

$HOLX vs. $LH — Which MedTech stock should you bet on? 🤔 Labcorp’s strategic partnerships and innovation in high-growth areas give it an edge, with analysts targeting a 19.3% upside. Meanwhile, Hologic's strength in diagnostics and breast health, along with M&A contributions, continue to support its performance. Find out which stock has the better outlook here 👉 https://www.zacks.com/stock/news/2807138/holx-vs-lh-which-medtech-stock-is-the-stronger-investment-now?cid=sm-stocktwits-2-2807138-body-25762&ADID=SYND_STOCKTWITS_TWEET_2_2807138_BODY_25762

0 · Reply

ZacksResearch Dec. 22 at 12:02 PM

$HOLX vs. $LH — only one can be the stronger MedTech play right now 👀 This head-to-head breaks down which of these two MedTech names stacks up better as an investment right now, cutting straight to the strengths that matter most for investors. See which stock comes out on top 👉 https://www.zacks.com/stock/news/2807138/holx-vs-lh-which-medtech-stock-is-the-stronger-investment-now?cid=sm-stocktwits-2-2807138-teaser-25719&ADID=SYND_STOCKTWITS_TWEET_2_2807138_TEASER_25719

0 · Reply

1iquid Dec. 20 at 5:59 PM

OptionWizards Tip (education only): When analyzing options on STLD, DXCM, or LH, review earnings dates to avoid unexpected volatility from announcements. $STLD $DXCM $LH Not financial advice.

0 · Reply

PrivateProfiteersAnalyst Dec. 19 at 3:55 PM

Actionable Trade Alert for $LH: Market Context: $LH closed at $252.03, significantly below both the 30-day MA of $261.82 and the 50-day MA of $266.36. The RSI at 25.91 indicates that the stock is oversold, suggesting potential for a reversal. The recent high of $293.72 provides a target for recovery, while the low of $244.52 establishes a support level. Directional Bias: Bearish sentiment has prevailed, but the oversold RSI indicates a potential bullish reversal. As the price is closer to the 60-day low, a bounce back towards the moving averages is plausible. Trade Plan: - Suggested Entry: $252.03 - Stop Loss: $244.00 (below recent low) - Take Profit Targets: - TP1: $261.00 (10% ROI) - TP2: $270.00 (7.1% ROI) - TP3: $295.00 (17% ROI) Monitor the price action closely and adjust stop loss as necessary to lock in profits. https://privateprofiteers.com

0 · Reply

PEDO_Trump_LLC Dec. 17 at 4:06 PM

$LH thought we'd be aiming at that $275 gap but, not yet

0 · Reply

PrivateProfiteersAnalyst Dec. 17 at 2:42 AM

Actionable Trade Alert for $LH: Market Context: $LH is currently trading at $258.36, with an RSI of 39.61 indicating it's in the oversold territory. The stock is below its 30-day moving average (MA30) of 261.9 and 50-day moving average (MA50) of 267.3, suggesting bearish momentum. However, the recent low of $244.52 provides a potential support level. Directional Bias: The bearish trend is evident, but the oversold RSI indicates a potential reversal. The price is closer to the 60D low, making it a candidate for a bounce back. Trade Plan: - Suggested Entry: $258.36 - Stop Loss: $244.00 (below 60D low) - Take Profit Targets: 1. $265.00 (Target 1 - 2.6% ROI) 2. $275.00 (Target 2 - 6.4% ROI) 3. $302.00 (Target 3 - 17% ROI) This trade leverages the potential for a rebound while managing risk effectively. Monitor the ATR of 4.78 for volatility adjustments. https://privateprofiteers.com

0 · Reply

PrivateProfiteersAnalyst Dec. 15 at 6:15 AM

Actionable Trade Alert for $LH: Market Context: $LH closed at $264.18, showing a stable position within the 60-day high of $293.72 and low of $244.52. The current RSI of 47.39 indicates a neutral market sentiment, suggesting potential for upward movement. Directional Bias: The price is above the 30-day moving average (MA30) of 261.78, indicating short-term bullish potential. However, it remains below the 50-day moving average (MA50) of 267.69, which may act as resistance. The ATR of 4.53 suggests moderate volatility. Trade Plan: - Suggested Entry: $265.00 - Stop Loss: $258.00 (risking $7.00) - Take Profit Targets: 1. $275.00 (3.77% ROI) 2. $285.00 (7.92% ROI) 3. $310.00 (17.36% ROI) This plan offers a solid risk-reward ratio, with a potential 17%+ ROI on the third target. Monitor market conditions closely to adjust as needed. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

0 · Reply

lauren_cooper88 Dec. 12 at 5:50 PM

$LH Mainz Biomed has the perfect microcap mechanics, 1.00–1.06 day range on ~122k mid-day volume means the book is thin, give it a 400–500k day and the stair to 1.10–1.12 then 1.15–1.20 is wide open with UK ~44,000 CRC cases backdrop

0 · Reply

PrivateProfiteersAnalyst Dec. 11 at 11:08 PM

Actionable Trade Alert for $LH: Market Context: $LH closed at $264.73, currently positioned between its 60D high of $293.72 and low of $244.52. The RSI at 55.16 indicates a neutral to slightly bullish momentum, suggesting potential for upward movement. Directional Bias: The price is above the 30-day moving average (MA30) of $261.39, indicating short-term bullish sentiment. However, it is below the 50-day moving average (MA50) of $267.99, which may act as resistance. The ATR of 4.83 suggests moderate volatility, allowing for reasonable price swings. Trade Plan: - Suggested Entry: $265.00 - Stop Loss: $260.00 (risking $5.00) - Take Profit Targets: 1. $270.00 (+1.89% ROI) 2. $280.00 (+5.70% ROI) 3. $310.00 (+16.98% ROI) With a potential 17% ROI on the third target, this trade offers a favorable risk-reward ratio. Monitor price action closely around the MA50 for further confirmation. https://privateprofiteers.com

0 · Reply

Cofactor Genomics Announces Strategic Investment by Labcorp and Ascension Ventures to Fuel Expansion of Its OncoPrism® Immunotherapy Diagnostic Across U.S. Cancer Care Networks

Dec 2, 2025, 4:15 PM EST - 22 days ago

Community Health Systems Completes Sale of Select Outreach Laboratory Assets to Labcorp

CYH

Nov 24, 2025, 8:30 AM EST - 4 weeks ago

Labcorp Appoints Victor Bulto to Board of Directors

Nov 19, 2025, 7:04 AM EST - 5 weeks ago

Labcorp® Plasma Detect™ Clinical Studies Featured in Nature Medicine and Clinical Cancer Research

Nov 17, 2025, 9:00 AM EST - 5 weeks ago

Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research

Oct 28, 2025, 2:45 PM EDT - 2 months ago

Labcorp Positioned For Gradual Upside With Resilient Margins And Dividend Support

Oct 28, 2025, 12:31 PM EDT - 2 months ago

Labcorp Holdings Inc. (LH) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 6:52 AM EDT - 2 months ago

Labcorp lifts annual profit forecast on strong diagnostic test demand

Oct 28, 2025, 6:50 AM EDT - 2 months ago

Labcorp Announces 2025 Third Quarter Results

Oct 23, 2025, 7:00 AM EDT - 2 months ago

Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings

Oct 20, 2025, 9:00 AM EDT - 2 months ago

Praia Health, Providence, and Labcorp Collaborate to Transform Patient Engagement and Lab Order Adherence

Oct 8, 2025, 4:15 PM EDT - 2 months ago

Labcorp Declares Quarterly Dividend

Sep 30, 2025, 7:00 AM EDT - 3 months ago

Labcorp Announces Collaboration with Roche to Advance Digital Pathology Capabilities

Sep 25, 2025, 4:15 PM EDT - 3 months ago

Labcorp to Announce Third Quarter Financial Results on October 28, 2025

Sep 15, 2025, 8:30 AM EDT - 3 months ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

OPK

Sep 9, 2025, 10:26 AM EDT - 3 months ago

Labcorp Holdings Inc. (LH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 27, 2025, 4:15 PM EDT - 4 months ago

Labcorp to Speak at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 18, 2025, 7:00 AM EDT - 4 months ago

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease

Jul 30, 2025, 7:12 AM EDT - 5 months ago

Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

Jul 29, 2025, 7:00 AM EDT - 5 months ago

Labcorp Achieves IVDR CE-Marking for PGDx elio™ tissue complete in the EU

Jul 25, 2025, 9:45 AM EDT - 5 months ago

These Analysts Boost Their Forecasts On Labcorp Following Better-Than-Expected Q2 Earnings

Jul 24, 2025, 2:38 PM EDT - 5 months ago

Labcorp Holdings Inc. (LH) Q2 2025 Earnings Call Transcript

Jul 24, 2025, 12:27 PM EDT - 5 months ago

Why Is Testing Giant Labcorp Stock Surging On Thursday?

Jul 24, 2025, 7:00 AM EDT - 5 months ago

Labcorp raises annual profit forecast on strong diagnostic testing demand

Jul 24, 2025, 6:50 AM EDT - 5 months ago

Labcorp Announces 2025 Second Quarter Results

Jul 22, 2025, 4:15 PM EDT - 5 months ago

Community Health Systems Announces Definitive Agreement to Sell Select Outreach Laboratory Assets to Labcorp

CYH

Jun 30, 2025, 6:58 AM EDT - 6 months ago

Labcorp Upgraded To A Buy As Portfolio Grows And Leverage Stays Low

Jun 26, 2025, 4:10 PM EDT - 6 months ago

Labcorp to Announce Second Quarter Financial Results on July 24, 2025

Jun 2, 2025, 7:00 AM EDT - 7 months ago

ASU, Labcorp, and InStride announce first-of-its-kind diagnostics industry partnership that tackles critical healthcare workforce shortage

May 30, 2025, 7:00 AM EDT - 7 months ago

Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

May 8, 2025, 4:15 PM EDT - 8 months ago

Labcorp to Webcast Its Annual Meeting of Shareholders May 15

Apr 29, 2025, 4:21 PM EDT - 8 months ago

Labcorp Holdings Inc. (LH) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 6:56 AM EDT - 8 months ago

Labcorp beats quarterly profit estimate on diagnostic test demand

Apr 29, 2025, 6:50 AM EDT - 8 months ago

Labcorp Announces 2025 First Quarter Results

Apr 23, 2025, 7:00 AM EDT - 8 months ago

Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions

Apr 11, 2025, 5:32 AM EDT - 9 months ago

Genetic Screening Testing for the Preventive Health Market, 2025-2035 Analysis - Dominated by Exact Science, Labcorp Genetics, Blueprint Genetics, Ambry Genetics, and Genex Diagnostics

Apr 2, 2025, 7:00 AM EDT - 9 months ago

Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease

Apr 1, 2025, 8:32 AM EDT - 9 months ago

Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide

Mar 31, 2025, 4:15 PM EDT - 9 months ago

Labcorp to Announce First Quarter Financial Results on April 29, 2025

Mar 11, 2025, 7:00 AM EDT - 10 months ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

OPK

Feb 24, 2025, 7:32 AM EST - 10 months ago

Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors

Feb 13, 2025, 2:12 PM EST - 11 months ago

Labcorp Holdings: Focus On Core Strengths For Future Growth, Initiate At 'Hold'

Feb 6, 2025, 3:42 PM EST - 11 months ago

Labcorp Holdings Inc. (LH) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 1:22 PM EST - 11 months ago

Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook

Feb 6, 2025, 6:55 AM EST - 11 months ago

Labcorp forecasts 2025 revenue above estimates on diagnostic test demand

Feb 6, 2025, 6:50 AM EST - 11 months ago

Labcorp Announces 2024 Fourth Quarter and Full Year Results

Jan 10, 2025, 4:15 PM EST - 1 year ago

Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 6:02 PM EST - 1 year ago

LABCORP DECLARES QUARTERLY DIVIDEND

Jan 8, 2025, 4:15 PM EST - 1 year ago

Labcorp to Announce Fourth Quarter Financial Results on February 6, 2025

Jan 8, 2025, 8:15 AM EST - 1 year ago

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

BIO

PrivateProfiteersAnalyst Dec. 25 at 2:00 PM

0 · Reply

ZacksResearch Dec. 22 at 1:57 PM

0 · Reply

ZacksResearch Dec. 22 at 12:02 PM

0 · Reply

1iquid Dec. 20 at 5:59 PM

OptionWizards Tip (education only): When analyzing options on STLD, DXCM, or LH, review earnings dates to avoid unexpected volatility from announcements. $STLD $DXCM $LH Not financial advice.

0 · Reply

PrivateProfiteersAnalyst Dec. 19 at 3:55 PM

0 · Reply

PEDO_Trump_LLC Dec. 17 at 4:06 PM

$LH thought we'd be aiming at that $275 gap but, not yet

0 · Reply

PrivateProfiteersAnalyst Dec. 17 at 2:42 AM

0 · Reply

PrivateProfiteersAnalyst Dec. 15 at 6:15 AM

0 · Reply

lauren_cooper88 Dec. 12 at 5:50 PM

0 · Reply

PrivateProfiteersAnalyst Dec. 11 at 11:08 PM

0 · Reply

PrivateProfiteersAnalyst Dec. 10 at 3:12 AM

Actionable Trade Alert for $LH: Market Context: $LH is currently trading at $258.06, within a range defined by a 60D high of $293.72 and a low of $244.52. The RSI at 46.71 indicates a neutral stance, suggesting potential for upward movement as it approaches oversold territory. Directional Bias: The price is below both the 30-day (MA30) at $260.76 and the 50-day (MA50) at $268.78, indicating bearish momentum. However, the proximity to the 60D low suggests a possible reversal opportunity. Trade Plan: - Suggested Entry: $258.50 - Stop Loss: $244.00 (below the 60D low) - Take Profit Targets: 1. $265.00 (2.5% ROI) 2. $275.00 (6.5% ROI) 3. $302.00 (17% ROI) This plan allows for a favorable risk-reward ratio, capitalizing on potential upward movement while managing risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

0 · Reply

PrivateProfiteersAnalyst Dec. 8 at 11:00 PM

Actionable Trade Alert for $LH: Market Context: $LH closed at $260.18, showing a neutral RSI at 47.75, indicating no immediate overbought or oversold conditions. The price is below both the 30-day MA (261.35) and the 50-day MA (269.28), suggesting a bearish trend in the short to medium term. However, the 60-day high of 293.72 offers a potential upside target. Directional Bias: The price is currently in the middle of its 60-day range (244.52 - 293.72), allowing for potential upward movement. The ATR of 4.74 indicates moderate volatility, which can be leveraged for profit-taking. Suggested Trade Plan: - Entry: $260.50 (slightly above the last close) - Stop Loss: $255.00 (risking $5.50) - Take Profit Targets: 1. $270.00 (3.5% gain) 2. $280.00 (7.5% gain) 3. $305.00 (17.3% gain) This plan allows for a structured approach with a favorable risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

0 · Reply

PrivateProfiteersAnalyst Dec. 6 at 2:00 AM

Actionable Trade Alert for $LH: Market Context: $LH is currently trading at $261.48, showing bearish momentum as indicated by the RSI of 38.63, which suggests potential oversold conditions. The price is below both the 30-day MA (262.85) and the 50-day MA (270.04), reinforcing the bearish sentiment. Directional Bias: The price is closer to the 60D low of $244.52 than the high of $293.72, indicating a potential for a rebound. However, caution is warranted due to the current bearish indicators. Trade Plan: - Suggested Entry: $261.50 - Stop Loss: $254.00 (risking approximately 2.85%) - Take Profit Targets: 1. $270.00 (Target 1, approx. 3.2% gain) 2. $280.00 (Target 2, approx. 7.1% gain) 3. $307.00 (Target 3, approx. 17.4% gain) This plan allows for a strategic entry with a favorable risk-to-reward ratio. Monitor the price action closely as it approaches the targets. https://privateprofiteers.com

0 · Reply

BillionerOfKing Dec. 3 at 1:36 AM

$LH Current Stock Price: $265.99 Contracts to trade: $270 LH Dec 19 2025 Call Entry: $2.90 Exit: $3.77 ROI: 30% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ZacksResearch Dec. 2 at 1:10 PM

$LH outperforms the industry — but is it a hold or buy? 🤔 Despite a Zacks Rank #3, Labcorp's strategic expansions in oncology and genetic testing are noteworthy alongside a 16.8% rally over the past year, outpacing the industry's 9.4% growth. Yet, macroeconomic challenges and currency headwinds loom. Discover the full investment case here 👉 https://www.zacks.com/stock/news/2798098/should-you-continue-to-hold-lh-stock-in-your-portfolio?cid=sm-stocktwits-2-2798098-body-22983&ADID=SYND_STOCKTWITS_TWEET_2_2798098_BODY_22983

0 · Reply

ZacksResearch Dec. 2 at 11:57 AM

Is $LH still worth holding here? ⚠️ When the headline itself is asking if you should “continue to hold,” that’s a clear signal this name is at an inflection point that investors can’t ignore. The full breakdown on whether LH still earns a spot in your portfolio 👉 https://www.zacks.com/stock/news/2798098/should-you-continue-to-hold-lh-stock-in-your-portfolio?cid=sm-stocktwits-2-2798098-teaser-22957&ADID=SYND_STOCKTWITS_TWEET_2_2798098_TEASER_22957

0 · Reply

OfficialStocktwitsUser Nov. 24 at 2:04 PM

$LH RSI: 57.69, MACD: -2.3687 Vol: 7.63, MA20: 259.45, MA50: 271.74 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

ZacksResearch Nov. 21 at 2:12 PM

$LH makes waves with innovative Plasma Detect tech! 🌊 📈 Featured in Nature Medicine and Clinical Cancer Research, this tech aids in predicting long-term survival and tracking early disease progression in diffuse pleural mesothelioma treatment. 🔬 Enhanced detection capabilities in post-surgery scenarios, especially for head and neck cancer. Discover how this could shape LH’s future prospects 👉 https://www.zacks.com/stock/news/2794023/lh-shares-gain-following-publication-of-new-plasma-detect-mrd-data?cid=sm-stocktwits-2-2794023-body-21987&ADID=SYND_STOCKTWITS_TWEET_2_2794023_BODY_21987

0 · Reply

ZacksResearch Nov. 21 at 1:12 PM

Big move brewing for $LH? New studies are putting Plasma Detect in the spotlight, showing its potential in tracking MRD and improving post-surgery cancer detection — and the shares are already edging higher on the news. Full breakdown here 👉 https://www.zacks.com/stock/news/2794023/lh-shares-gain-following-publication-of-new-plasma-detect-mrd-data?cid=sm-stocktwits-2-2794023-teaser-21986&ADID=SYND_STOCKTWITS_TWEET_2_2794023_TEASER_21986

0 · Reply

notreload_ai Nov. 13 at 5:09 PM

$HIMS , $DGX , $LH ... Hims & Hers Health launches lab testing with Quest Diagnostics, offering affordable biomarker tests and personalized health plans as part of its preventive care expansion. https://notreload.xyz/hims-launches-affordable-lab-testing/

0 · Reply

JarvisFlow Nov. 7 at 7:55 PM

JP Morgan updates rating for Labcorp Hldgs ( $LH ) to Overweight, target set at 291 → 317.

0 · Reply

SuperGreenToday Nov. 4 at 3:24 PM

$LH Share Price: $253.91 Contract Selected: May 15, 2026 $250 Calls Buy Zone: $18.45 – $22.79 Target Zone: $30.26 – $36.98 Potential Upside: 55% ROI Time to Expiration: 191 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Market Cap	20.99B
Revenue (ttm)	13.01B
Net Income (ttm)	746.00M
EPS (ttm)	N/A
PE Ratio	16.12
Forward PE	15.62
Profit Margin	5.73%
Debt to Equity Ratio	0.58

Volume	427,600
Avg Vol	876,174
Day's Range	N/A - N/A
Shares Out	82.90M
Stochastic %K	22%
Beta	0.99
Analysts	Strong Sell
Price Target	$300.70